ERA4Health: Launch of the Transnational Call for Clinical Trials IICS4all 2027

The Ministry of Health (hereinafter “MoH”) is publishing onOctober 29, 2026, in accordance with Act No. 130/2002 Coll., on the Support of Research, Experimental Development, and Innovation from Public Funds and on Amendments to Certain Related Acts (the Act on the Support of Research, Experimental Development, and Innovation), as amended (hereinafter referred to as the “Act”),

a transnational call for proposals focused on clinical studies under the ERA4Health partnership (Fostering a European Research Area for Health): “Multi-national Investigator-Initiated Clinical Studies in Cardiovascular, Autoimmune, Metabolic, and Non-Communicable Respiratory Diseases, including Underrepresented Populations” (ICS4all 2027)

Call 2027

Date of announcement of results
, October 2027

National budget allocation for the call
500 000 EUR

Maximum amount of support per project
250 000 EUR

Maximum aid intensity per project
Table: Maximum possible aid intensity by type of entity and type of research (according to the current version Methodology: European Partnerships in Health)

Applicants
nd a research organization, a company, or a patient organization

project duration: 3 years / 36 months ( for Czech applicants)

Deadlines for submitting project proposals:
Pre-proposals: January 14, 2027, 12:00 p.m. CET
Full proposals: June 14, 2027, 12:00 p.m. CEST

Those interested can participate inan international informational webinar, which will take placeon November 10, 2026 (from 2:30 p.m. to 4:30 p.m. CET). Registration is available at this link: REGISTRATION

Documents

Conditions for the Participation of a Czech Applicant in ERA4Health IICS4all 2027

Methodology: European Partnerships for Health

Sub-programme 3: European Partnerships in Health - effective from 22.5.2024

Mandatory attachments of the Czech applicant for Phase 1 (pre-proposals)

Mandatory annexes of the Czech applicant for Phase 2 (full proposals)

Affidavit of competence;
Updated budget table AZV ČR Application Form)

Other documents

Commission Regulation

Frascati manual

Definition of types of results

The official call documents are available here

Information about the call

The ERA4Health transnational call for proposals: “Multinational Investigator-Initiated Clinical Studies in Cardiovascular, Autoimmune, Metabolic, and Noncommunicable Respiratory Diseases, including Underrepresented Populations” (ICS4all 2027) aims to:

to support pragmatic, randomized controlled, international Phase III intervention clinical trials initiated by researchers (Investigator-Initiated Clinical Studies, IICS).

Two types of studies will be supported:

comparative effectiveness studies;
drug repurposing studies of off-patent drugs.

Studies must focus on at least one or a combination of the following areas:

cardiovascular disease;
metabolic disorders;
autoimmune diseases;
non-communicable respiratory diseases.

At the same time, emphasis is placed on involving diverse groups of patients, taking into account their gender, age, and other relevant characteristics.

Projects should take into account the following aspects:

The design of a clinical trial must be appropriately chosen to enable the research question to be answered (study population, sampling, statistical analysis, interpretation of results, and relevant models for testing the hypothesis…), and must be properly justified in the study protocol.
The design and objectives of a clinical trial must take into account the participant population needed to achieve the study’s stated objective. The protocol must include strategies for recruiting and retaining participants, their evaluation , and data analysis.
In comparative efficacy studies, the use of currently approved or existing medical interventions used in clinical practice is compared, either with one another or with the current standard of care.
In the case of studies focused on new uses for drugs, the goal is to investigate new indications for approved drugs. Since this call for proposals is funded by public funds, clinical trials conducted for commercial purposes are excluded; therefore, only studies focused on new uses for drugs whose patent protection has already expired are permitted.

Clinical trials conducted for direct commercial purposes and/or in medical fields other than those mentioned above are not covered by this call.

Size of the project consortium

Each project consortium must include eligible partners applying for funding through their respective funding organizations/agencies from at least three and no more than five countries (eligible partners) participating in this call. At the same time , at least two partners must come from two different countries that are either EU Member States or countries associated with the Horizon Europe Framework Program.Theprojectcoordinatormust be eligible for funding from its regional/national funding organization participating in the call. The project coordinator may not be changed between the first and second phases. A maximum of3 self-funded partnersare allowed in the consortium.The maximum number of countries may be increased to 6 if they include Slovakia as an underrepresented country. Only transnational projects will be funded.

List of participating countries:

Austria (FWF), Belgium (KCE), the Czech Republic (MZČR/AZVČR), Egypt (ASRT), France (FR MOH), Germany (BMFTR/DLR), Ireland (HRB), Israel (CSO-MOH), Italy (FRRB), Latvia (LCS), Lithuania (LMT), Norway (RCN and HSØRHF), Poland (NCBR), Romania (UEFISCDI), Slovakia (CVTI SR), Spain (CPSEJA, ISCIII, and DS-CAT), Sweden (SRC), Turkey (TÜSEB), and the global organization Breakthrough T1D.

*The list of participating countries is current as of October 27, 2026.

Call rules:

The call is governed by transnational rules common to applicants from all participating countries. In addition to the transnational rules, Czech applicants must also comply with the national conditions set by the relevant national provider. Applicants participating in applied research projects will therefore have to comply with national conditions based on Sub-programme 3: European Partnerships in Health.

Contact person:

Mgr. Monika Kocmanová
Email:
Tel: +420 778 973 186

You can also submit questions about the transnational call via email: .